David A. Canton

1.3k total citations
38 papers, 831 citations indexed

About

David A. Canton is a scholar working on Molecular Biology, Oncology and Biotechnology. According to data from OpenAlex, David A. Canton has authored 38 papers receiving a total of 831 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Biotechnology. Recurrent topics in David A. Canton's work include Microbial Inactivation Methods (10 papers), Protein Kinase Regulation and GTPase Signaling (9 papers) and CAR-T cell therapy research (7 papers). David A. Canton is often cited by papers focused on Microbial Inactivation Methods (10 papers), Protein Kinase Regulation and GTPase Signaling (9 papers) and CAR-T cell therapy research (7 papers). David A. Canton collaborates with scholars based in United States, Canada and Australia. David A. Canton's co-authors include David W. Litchfield, Cunjie Zhang, Greg Vilk, John D. Scott, John A. Cooper, Ronald B. Saulnier, Denis G. Bosc, Robert H. Pierce, Richard J. Connolly and Jean S. Campbell and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Neuroscience and Molecular Cell.

In The Last Decade

David A. Canton

34 papers receiving 811 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David A. Canton United States 17 548 204 186 128 87 38 831
Douglas A. Austen United States 9 613 1.1× 176 0.9× 188 1.0× 69 0.5× 61 0.7× 12 861
Nichole Giles Australia 19 683 1.2× 152 0.7× 316 1.7× 52 0.4× 53 0.6× 27 927
Carolyn N. Wrobel United States 7 605 1.1× 214 1.0× 130 0.7× 109 0.9× 64 0.7× 8 837
Rebecca M. Perrett United Kingdom 16 810 1.5× 166 0.8× 100 0.5× 97 0.8× 192 2.2× 26 1.1k
Eric M. Sandberg United States 10 385 0.7× 166 0.8× 137 0.7× 89 0.7× 89 1.0× 15 638
Karen L. Abbott United States 20 1.1k 2.0× 174 0.9× 133 0.7× 319 2.5× 78 0.9× 34 1.3k
Penny K. Davis United States 8 600 1.1× 366 1.8× 124 0.7× 84 0.7× 59 0.7× 10 813
Maud Martin Belgium 17 818 1.5× 135 0.7× 436 2.3× 98 0.8× 89 1.0× 34 1.1k
Mantu Bhaumik United States 18 1.3k 2.3× 198 1.0× 171 0.9× 197 1.5× 231 2.7× 32 1.5k
Minna Eriksson Finland 12 463 0.8× 235 1.2× 126 0.7× 51 0.4× 188 2.2× 14 684

Countries citing papers authored by David A. Canton

Since Specialization
Citations

This map shows the geographic impact of David A. Canton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Canton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Canton more than expected).

Fields of papers citing papers by David A. Canton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Canton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Canton. The network helps show where David A. Canton may publish in the future.

Co-authorship network of co-authors of David A. Canton

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Canton. A scholar is included among the top collaborators of David A. Canton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Canton. David A. Canton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tarhini, Ahmad A., Zeynep Eroglu, Jonathan S. Zager, et al.. (2024). Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma. Clinical Cancer Research. 30(23). 5333–5341. 4 indexed citations
2.
3.
4.
Lee, Jack Y., Bianca Nguyen, Anandaroop Mukhopadhyay, et al.. (2022). Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity. Molecular Therapy — Oncolytics. 25. 174–188. 10 indexed citations
5.
Lee, Jack Y., et al.. (2022). Abstract P006: Intratumoral electroporation of IL-12 and SARS-Cov-2 spike plasmids drives a coordinated vaccine response and elicits robust anti-tumor immunity. Cancer Immunology Research. 10(1_Supplement). P006–P006. 1 indexed citations
6.
Burkart, Christoph, A. Mukhopadhyay, Shawna A. Shirley, et al.. (2018). Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters. Gene Therapy. 25(2). 93–103. 22 indexed citations
7.
Mukhopadhyay, Anandaroop, Jocelyn H. Wright, Shawna A. Shirley, et al.. (2018). Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy. Gene Therapy. 26(1-2). 1–15. 43 indexed citations
8.
Brown, Douglas W., David A. Canton, Anandaroop Mukhopadhyay, et al.. (2018). Development of an adaptive electroporation system for intratumoral plasmid DNA delivery. Bioelectrochemistry. 122. 191–198. 7 indexed citations
9.
Cherry, Allison E., Brian R. Haas, Alipi V. Naydenov, et al.. (2016). ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme. Molecular Cancer Therapeutics. 15(9). 2018–2029. 23 indexed citations
10.
Havekes, Robbert, David A. Canton, Alan Jung Park, et al.. (2012). Gravin Orchestrates Protein Kinase A and β2-Adrenergic Receptor Signaling Critical for Synaptic Plasticity and Memory. Journal of Neuroscience. 32(50). 18137–18149. 58 indexed citations
11.
Canton, David A., C. Dirk Keene, Lorene K. Langeberg, et al.. (2012). Gravin Is a Transitory Effector of Polo-like Kinase 1 during Cell Division. Molecular Cell. 48(4). 547–559. 28 indexed citations
12.
Guzman, Michael J., et al.. (2011). A study of the prevalence of vitamin B12 deficiency in Turlock, California. 3(5). 195–201. 1 indexed citations
13.
Tienken, Christopher H. & David A. Canton. (2009). National Curriculum Standards: Let’s Think It Over. 6(3). 3–9. 10 indexed citations
14.
Paulucci-Holthauzen, Adriana, et al.. (2008). Spatial Distribution of Protein Kinase A Activity during Cell Migration Is Mediated by A-kinase Anchoring Protein AKAP Lbc. Journal of Biological Chemistry. 284(9). 5956–5967. 45 indexed citations
15.
Canton, David A., et al.. (2006). The Role of CKIP-1 in Cell Morphology Depends on Its Interaction with Actin-capping Protein. Journal of Biological Chemistry. 281(47). 36347–36359. 52 indexed citations
16.
Canton, David A. & David W. Litchfield. (2005). The shape of things to come: An emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cellular Signalling. 18(3). 267–275. 85 indexed citations
17.
Canton, David A., Kyoungtae Kim, Amanda Doherty-Kirby, et al.. (2005). The Pleckstrin Homology Domain-Containing Protein CKIP-1 Is Involved in Regulation of Cell Morphology and the Actin Cytoskeleton and Interaction with Actin Capping Protein. Molecular and Cellular Biology. 25(9). 3519–3534. 66 indexed citations
18.
Zhang, Cunjie, Greg Vilk, David A. Canton, & David W. Litchfield. (2002). Phosphorylation regulates the stability of the regulatory CK2β subunit. Oncogene. 21(23). 3754–3764. 62 indexed citations
19.
Canton, David A., Cunjie Zhang, & David W. Litchfield. (2001). Assembly of protein kinase CK2: investigation of complex formation between catalytic and regulatory subunits using a zinc-finger-deficient mutant of CK2β. Biochemical Journal. 358(1). 87–87. 34 indexed citations
20.
Litchfield, David W., Denis G. Bosc, David A. Canton, et al.. (2001). Functional specialization of CK2 isoforms and characterization of isoform-specific binding partners. PubMed. 227(1-2). 21–29. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas A. Austen Breakdown of academic impact, for papers by Nichole Giles Breakdown of academic impact, for papers by Carolyn N. Wrobel Breakdown of academic impact, for papers by Rebecca M. Perrett Breakdown of academic impact, for papers by Eric M. Sandberg Breakdown of academic impact, for papers by Karen L. Abbott Breakdown of academic impact, for papers by Penny K. Davis Breakdown of academic impact, for papers by Maud Martin Breakdown of academic impact, for papers by Mantu Bhaumik Breakdown of academic impact, for papers by Minna Eriksson
Rankless by CCL
2026